Marshall Wace, LLP Assembly Biosciences, Inc. Transaction History

Marshall Wace, LLP

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2020 Aug 13, 2020	SELL	$14.57 - $23.96 $56,793 - $93,396	-3,898 Closed	0 $0
Q1 2020 May 15, 2020	SELL	$10.27 - $21.23 $1.23 Million - $2.55 Million	-120,149 Reduced 96.86%	3,898 $58,000
Q4 2019 Feb 14, 2020	BUY	$8.36 - $23.81 $632,216 - $1.8 Million	75,624 Added 156.17%	124,047 $2.54 Million
Q3 2019 Nov 14, 2019	BUY	$9.83 - $14.82 $236,254 - $356,183	24,034 Added 98.54%	48,423 $476,000
Q2 2019 Aug 14, 2019	SELL	$12.9 - $20.8 $2.52 Million - $4.07 Million	-195,443 Reduced 88.91%	24,389 $330,000
Q1 2019 May 14, 2019	SELL	$17.7 - $24.93 $2.16 Million - $3.04 Million	-121,939 Reduced 35.68%	219,832 $4.33 Million
Q4 2018 Feb 14, 2019	BUY	$19.05 - $36.45 $753,618 - $1.44 Million	39,560 Added 13.09%	341,771 $7.73 Million
Q3 2018 Nov 14, 2018	BUY	$34.41 - $44.23 $10.4 Million - $13.4 Million	302,211 New	302,211 $11.2 Million

16.3K

Ticker ASMB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 48,436,900
Market Cap $723M
Description
Assembly Biosciences, Inc., a clinical-stage biotechnology company, discovers and develops therapeutic candidates for the treatment of hepatitis B virus (HBV) infection in the United States. The company's lead product candidate is Vebicorvir, which as completed Phase 2 clinical trials to treat patients with chronic HBV infection. It is also deve...

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

Stay updated on Marshall Wace, LLP with notifications on news.